eFFECTOR Therapeutics Doses First Patient in Phase 2b KICKSTART Clinical Trial

SAN DIEGO, June 9, 2021 – eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulation inhibitors (STRIs) for the treatment of cancer, today announced that the first patient with non-small cell lung cancer (NSCLC) has been dosed in a Phase 2b trial of tomivosertib in combination with KEYTRUDA® (pembrolizumab).

eFFECTOR Therapeutics and Locust Walk Acquisition Corp. Announce Merger Agreement to Create Publicly Listed, Next-Generation Oncology Company Developing New Class of Cancer Therapies

SAN DIEGO, May 27, 2021 – eFFECTOR Therapeutics, Inc. (eFFECTOR), a biopharmaceutical company focused on pioneering the development of selective translation regulation inhibitors (STRIs) for the treatment of cancer, and Locust Walk Acquisition Corp.

eFFECTOR and Quantitative Biosciences Institute (QBI) at UCSF Receive $5.0 Million from DARPA to Evaluate Zotatifin in COVID-19

SAN DIEGO, May 4, 2021 – eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced a $5.0 million cooperative agreement sponsored by the Defense Advanced Research Projects Agency (DARPA) and the Defense Health Agency (DHA)

eFFECTOR Appoints Mike Byrnes as Chief Financial Officer

SAN DIEGO, Jan. 7, 2021 – eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulation inhibitors (STRIs) for the treatment of cancer, today announced that it has appointed Mike Byrnes as chief financial officer.

eFFECTOR Announces Dosing of First Breast Cancer Patient with Tomivosertib in Combination with Chemotherapy Through a Grant from Stand Up To Cancer® (SU2C) Canada

SAN DIEGO, Nov. 12, 2020 (GLOBE NEWSWIRE) — eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulation inhibitors (STRIs) for the treatment of cancer, today announced that the first breast cancer patient has been dosed with a combination of tomivosertib and paclitaxel in a Phase 2 study led by McGill University in Canada.

eFFECTOR’s Zotatifin (eFT226) Downregulates Key Oncogenic Driver Proteins Including RTKs (HER2, FGFR1 and FGFR2) Providing Single Agent Activity and Key Combination Opportunities

SAN DIEGO, OCTOBER 26, 2020 – eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulation inhibitors (STRIs) for the treatment of cancer, today announced that data presented over the weekend at the EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium (ENA 2020)

eFFECTOR Appoints Premal Patel, M.D., Ph.D., as Chief Medical Officer

SAN DIEGO, Oct. 15, 2020 — eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced the appointment of Premal Patel, M.D., Ph.D., as chief medical officer.

eFFECTOR’s Tomivosertib Demonstrates Positive Phase 2 Results for Subjects with Non-Small Cell Lung Cancer in Combination with Checkpoint Inhibitors

SAN DIEGO, MAY 29, 2020 – eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulation inhibitors (STRIs) for the treatment of cancer, today announced that positive Phase 2 data from its pipeline program tomivosertib (eFT508)

eFFECTOR’s Zotatifin Demonstrates in vitro Anti-SARS-CoV-2 Activity in Independent International Study Reported in Peer-Reviewed Journal Nature

SAN DIEGO, April 30, 2020 – eFFECTOR Therapeutics, Inc., today announced that preliminary results from an independent preclinical study showed that oncology product candidate zotatifin (eFT226) had in vitro antiviral activity against SARS-CoV-2, the virus that causes COVID-19. The results of the research

eFFECTOR’s Zotatifin (eFT226) Inhibited Tumor Growth and Caused Tumor Regression Across Diverse Receptor Tyrosine Kinase-Driven Tumor Types in Preclinical Models of Disease

SAN DIEGO, April 27, 2020 (GLOBE NEWSWIRE) — eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, announced that data presented today in a virtual session at the AACR Annual Meeting,